Merck and Moderna Cancer Vaccine Succeeds in Major Trial

Cancer patients could soon have a powerful new weapon in their fight, thanks to a groundbreaking vaccine that trains the body to hunt down and destroy its own tumors.

Merck and Moderna announced Wednesday that their experimental personalized cancer vaccine met all major goals in a Phase 3 trial involving more than 1,100 melanoma patients. When combined with Merck's immunotherapy drug Keytruda, the vaccine significantly extended the time patients lived without their cancer returning compared to Keytruda alone.

The vaccine also reduced the risk of melanoma spreading to distant parts of the body. These results build on promising earlier trial data from this year, bringing the companies one step closer to seeking FDA approval.

Melanoma accounts for only 1% of skin cancers but causes the vast majority of skin cancer deaths. Most recurrences happen within two to three years after initial treatment and surgery, leaving patients anxious about whether their cancer will return.

"It's a big moment for medicine, a big moment for patients," Moderna CEO Stephane Bancel told CNBC.

What makes this vaccine revolutionary is its personalized approach. Every tumor has a unique set of mutations, even among patients with the same type of cancer. Rather than using a one-size-fits-all treatment, this vaccine is custom-made for each patient to target their tumor's specific genetic fingerprint.

The technology trains the immune system to recognize and attack those unique cancer markers. When paired with Keytruda, which helps remove the brakes on the immune system, the combination delivers a powerful one-two punch against cancer cells.

Patients tolerated the treatment well, with side effects similar to other common vaccines. The drugmakers plan to present detailed data at an upcoming medical conference and expect to begin discussions with regulatory agencies "in the next few months," according to Dr. Dean Li, president of Merck Research Laboratories.

The Ripple Effect

This success extends far beyond melanoma patients. Merck and Moderna are already testing the personalized vaccine approach in trials for non-small cell lung cancer, bladder cancer, and kidney cancer. If the technology works across multiple cancer types, it could transform how we fight one of humanity's deadliest diseases.

Dr. Jane Healy, Merck's head of oncology early development, called the results validation of a personalized treatment approach both companies have been developing for decades. The stock market agreed: Moderna's shares soared nearly 150% on the news, while Merck climbed more than 10%.

The Phase 3 study will continue monitoring patients to assess overall survival benefits.

For cancer patients who undergo surgery and then live with the daily fear of recurrence, this vaccine offers something precious: hope backed by science.